IRIC discoveries have spurred major advances in understanding the development of cancer and opened the way to the creation of new, more targeted therapeutic solutions. Its publications are a reflection of these accomplishments. They also demonstrate the Institute’s drive and productivity.
Noncoding regions are the main source of targetable tumor-specific antigens.Sci Transl Med 2018-12-05;10(470).
FZD5 is a Gαq-coupled receptor that exhibits the functional hallmarks of prototypical GPCRs.Sci Signal 2018-12-04;11(559).
Functional selectivity profiling of the angiotensin II type 1 receptor using pathway-wide BRET signaling sensors.Sci Signal 2018-12-04;11(559).
PP2A-B55 promotes nuclear envelope reformation after mitosis in Drosophila.J. Cell Biol. 2018-12-03;217(12):4106-4123.
Detecting short RNA sequences of pathogens.Nat Nanotechnol 2018-12-01;13(12):1094-1096.
Evidence for a role of spindle matrix formation in cell cycle progression by antibody perturbation.PLoS ONE 2018-11-28;13(11):e0208022.
The Impact of Post-transcriptional Control: Better Living Through RNA Regulons.Front Genet 2018-11-05;9:512.
Structural insights into binding specificity, efficacy and bias of a β2AR partial agonist.Nat. Chem. Biol. 2018-11-01;14(11):1059-1066.
Spatiotemporal regulation of the GPCR activity of BAI3 by C1qL4 and Stabilin-2 controls myoblast fusion.Nat Commun 2018-10-26;9(1):4470.